New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
26th May 2023
10th May 2023
Chile: A bill allowing home growing of cannabis for medicinal purposes under prescription, approved in March by both the Chamber of Deputies and the Senate, was signed into law yesterday (9th May) by president Gabriel Boric.
26th April 2023
3rd April 2023
15th March 2023
14th March 2023
Chile: The Chamber of Deputies yesterday approved a report by an inter-house committee that seeks to allow home growing of cannabis for medicinal purposes provided the patient has a doctor’s prescription. The committee, made up of members of both the Senate and the Chamber of Deputies, was set up to agree a common position on a bill already in the legislative process.
28th November 2022
9th November 2022
Chile: The Senate decided yesterday to drop provisions allowing cultivation of cannabis for medicinal purposes, possession and cultivation of up to 500 g of cannabis and personal possession of up to 40 g from a bill amending several laws, including Law 20,000 on Narcotics. The bill is moving forward without the provisions relating to cannabis.
10th August 2022
Chile: The Senate Public Security Committee has approved modifications to a bill amending several laws, including Law 20,000 on Narcotics, that would allow the possession of up to five cannabis plants for personal use and up to 500 g of dry flower, and the carrying of up to 40 g.
14th June 2022
Chile: A group of parliamentarians within the ruling coalition said yesterday that they intend to present a bill to Parliament to legalise recreational cannabis, press reports. They will pursue the modification of Law 20,000 on Narcotics to regulate sales and use.
14th February 2022
Chile: A citizens’ initiative seeking to introduce a right to self-cultivation and consumption of cannabis for medicinal and recreational purposes, which gathered more than 44,000 signatures, has been rejected by the Constitutional Commission.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.